Last $0.33 HKD
Change Today 0.00 / 0.00%
Volume 1.0M
858 On Other Exchanges
Symbol
Exchange
Hong Kong
As of 3:01 AM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

extrawell pharmaceutical (858) Snapshot

Open
$0.33
Previous Close
$0.33
Day High
$0.33
Day Low
$0.32
52 Week High
03/3/14 - $0.61
52 Week Low
12/29/14 - $0.31
Market Cap
776.8M
Average Volume 10 Days
1.4M
EPS TTM
$0.10
Shares Outstanding
2.4B
EX-Date
07/24/00
P/E TM
3.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for EXTRAWELL PHARMACEUTICAL (858)

Related News

No related news articles were found.

extrawell pharmaceutical (858) Related Businessweek News

No Related Businessweek News Found

extrawell pharmaceutical (858) Details

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. It operates through Manufacturing, Trading, Gene Development, and Oral Insulin segments. The company offers Transfer Factor Oral Solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. It also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels; Feining Pian, which is used for the treatment of chronic cough, acute upper respiratory tract infection, infection associated with bronchitis, and emphysema; and YouHuanPing, a sustained-release tablet for sideropenic anemia. In addition, the company is involved in the marketing and distribution of imported pharmaceutical products, including GM-1 to treat lesions of central nervous system due to vascular or traumatic events and Parkinson's disease; Millibar for the treatment of high blood pressure; and Skin-Cap for use in the treatment of psoriasis, dandruff, dermatitis, atopic dermatitis, eczema, and tinea. Further, it is engaged in the commercial exploitation and development of genome-related technology; development and commercialization of oral insulin products; provision of agency services; and property investment business. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.

305 Employees
Last Reported Date: 12/11/14

extrawell pharmaceutical (858) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.1M
Honorary Chairman and Chief Scientific Adviso...
Total Annual Compensation: $340.0K
Qualified Accountant, Financial Controller, J...
Total Annual Compensation: $275.0K
Executive Director
Total Annual Compensation: $363.0K
Executive Director
Total Annual Compensation: $148.0K
Compensation as of Fiscal Year 2014.

extrawell pharmaceutical (858) Key Developments

Extrawell Pharmaceutical Holdings Ltd. Reports Unaudited Consolidated Cash Flow Results for the Six Months Ended September 30, 2014

Extrawell Pharmaceutical Holdings Ltd. reported unaudited consolidated cash flow results for the six months ended September 30, 2014. For the period, the company reported net cash used in operating activities of HKD 5,403,000 against HKD 3,639,000 for the same period a year ago.

Extrawell Pharmaceutical Holdings Ltd. Announces Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2014

Extrawell Pharmaceutical Holdings Ltd. announced unaudited consolidated earnings results for the six months ended September 30, 2014. For the period, the company reported turnover of HKD 74,308,000 against HKD 69,612,000 a year ago. Profit from operations was HKD 229,658,000 against HKD 7,254,000 a year ago. Profit before taxation was HKD 232,636,000 against HKD 5,164,000 a year ago. Profit for the period attributable to equity holders of the company was HKD 239,415,000 or 7.42 cents per diluted share against HKD 4,772,000 or nil cents per diluted share a year ago.

Extrawell Pharmaceutical Holdings Ltd. to Report First Half, 2015 Results on Nov 28, 2014

Extrawell Pharmaceutical Holdings Ltd. announced that they will report first half, 2015 results on Nov 28, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
858:HK $0.33 HKD 0.00

858 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 858.
View Industry Companies
 

Industry Analysis

858

Industry Average

Valuation 858 Industry Range
Price/Earnings 3.7x
Price/Sales 5.0x
Price/Book 0.7x
Price/Cash Flow 3.1x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXTRAWELL PHARMACEUTICAL, please visit www.extrawell.com.hk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.